You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫思健康(02138.HK)獲鄭志剛及Aspex認購配售股份增持 先舊後新配股籌2.49億
阿思達克 07-09 08:24
醫思健康(02138.HK)公布,公司主席兼執行董事鄧志輝作為賣方計劃向新世界發展(00017.HK)執行副主席鄭志剛及Aspex Master Fund先配售2,797萬股(佔現行股本2.52%)現有股份,每股認購價14.5元,較昨收市價14.94元折讓2.95%。

而醫思健康再向鄧志輝配售1,721.38萬股新股份(佔後經擴大已發行股份總數約1.53%),每股配售價為14.5元,公司預計,配售所得款項淨額估計約為2.49億元,將用於擴大集團於香港及內地大灣區的診所網絡、併購及集團的一般企業用途。

完成交易後,由於配售及認購事項,賣方鄧志輝對醫思健康總股權百分比將由約65.83%降至63.87%。買家鄭志剛及Aspex Master Fund對醫思健康的持股量會由原來4.11%增至6.53%。

醫思健康於4月中曾公布,計劃配售2,963.6萬股股份予新世界發展執行副主席鄭志剛及以私人投資基金形式營運的Aspex Master Fund。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account